oliceridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
analgesics, pethidine derivatives 5406 1401028-24-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oliceridine
  • olinvyk
  • TRV130
  • TRV-130
  • TRV 130A
  • olinvo
Oliceridine is a full opioid agonist and is relatively selective for the mu-opioid receptor. The principal therapeutic action of oliceridine is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oliceridine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
  • Molecular weight: 386.55
  • Formula: C22H30N2O2S
  • CLOGP: 3.32
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 43.38
  • ALOGS: -5.47
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 7, 2020 FDA TREVENA INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02AX07 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Other opioids

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Moderate pain indication 50415004
Severe pain indication 76948002
Paralytic ileus contraindication 55525008 DOID:8442
Decreased respiratory function contraindication 80954004
Gastrointestinal obstruction contraindication 126765001
Asthma contraindication 195967001 DOID:2841




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1MG/ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 11077098 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
1MG/ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 8835488 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
1MG/ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 9309234 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
1MG/ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 9642842 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
2MG/2ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 11077098 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
2MG/2ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 8835488 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
2MG/2ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 9309234 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
2MG/2ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 9642842 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
30MG/30ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 11077098 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
30MG/30ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 8835488 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
30MG/30ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 9309234 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
30MG/30ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS 9642842 March 23, 2032 MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1MG/ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS Oct. 30, 2025 NEW CHEMICAL ENTITY
2MG/2ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS Oct. 30, 2025 NEW CHEMICAL ENTITY
30MG/30ML (1MG/ML) OLINVYK TREVENA N210730 Oct. 30, 2020 RX SOLUTION INTRAVENOUS Oct. 30, 2025 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST Ki 8.22 DRUG LABEL DRUG LABEL
Sodium channel protein type 5 subunit alpha Ion channel IC50 5.33 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.21 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 4.44 CHEMBL
Nociceptin receptor GPCR AGONIST EC50 7.40 SCIENTIFIC LITERATURE

External reference:

IDSource
D11214 KEGG_DRUG
MCN858TCP0 UNII
C4508938 UMLSCUI
CHEMBL2443262 ChEMBL_ID
66553195 PUBCHEM_CID
DB14881 DRUGBANK_ID
7334 IUPHAR_LIGAND_ID
2392230 RXNORM
341480 MMSL
d09691 MMSL
897038008 SNOMEDCT_US
897041004 SNOMEDCT_US
4039828 VANDF
018475 NDDF
C586842 MESH_SUPPLEMENTAL_RECORD_UI
10250 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OLINVYK HUMAN PRESCRIPTION DRUG LABEL 1 71308-011 INJECTION, SOLUTION 1 mg INTRAVENOUS NDA 31 sections
OLINVYK HUMAN PRESCRIPTION DRUG LABEL 1 71308-021 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 31 sections
OLINVYK HUMAN PRESCRIPTION DRUG LABEL 1 71308-301 INJECTION, SOLUTION 30 mg INTRAVENOUS NDA 31 sections